VTRS Q1 2024 Earnings — Viatris Inc. Revenue & Financial Results | Market Cap Arena

VTRSViatris Inc.

$17B

Q1 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$3.7B-1.8% YoY

Gross Profit

$1.5B41.1% margin

Operating Income

$204M5.6% margin

Net Income

$114M3.1% margin

EPS (Diluted)

$0.09

QoQ Revenue Growth

-4.5%

Cash Flow

Operating Cash Flow

$615M

Free Cash Flow

$564M

Stock-Based Comp.

$47M

Balance Sheet

Total Assets

$47.3B

Total Liabilities

$27.3B

Stockholders' Equity

$20.0B

Cash & Equivalents

$1.0B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.7B	$3.7B	-1.8%
Gross Profit	$1.5B	$1.5B	-2.5%
Operating Income	$204M	$400M	-49.0%
Net Income	$114M	$225M	-49.3%

Revenue Segments

Brands

$2.3B63%

Generics

$1.3B37%

Geographic Segments

Developed Markets Segment

$2.2B59%

Emerging Markets Segment

$626M17%

Greater China Segment

$544M15%

Japan, Australia and New Zealand Segment

$318M9%